ID   SW620-OX
AC   CVCL_4V76
DR   cancercelllines; CVCL_4V76
DR   Wikidata; Q54971187
RX   PubMed=24761924;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:31941; Oxaliplatin (Elotaxin; L-OHP).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000027.
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0547 ! SW620
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 15
//
RX   PubMed=24761924; DOI=10.7314/APJCP.2014.15.6.2911;
RA   Chian S., Li Y.-Y., Wang X.-J., Tang X.-W.;
RT   "Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell
RT   lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.";
RL   Asian Pac. J. Cancer Prev. 15:2911-2916(2014).
//